CARA - Bathi operasional EBITDA Cara Therapeutics Inc.

Total EBITDA for the period demonstrates the resilience of Cara Therapeutics, Inc. (CARA) to macroeconomic fluctuations, as demand for renal pruritus treatment remains stable. 0.00 captures the current value of the indicator. The brand is renowned for innovations in opioid receptor targeting to assist hemodialysis patients. However, the absence of commercial sales and R&D expenditures create a heavy dependence on clinical trial outcomes.
caratherapeutics.com (CARA) - rincian metrik lan laporan keuangan

Royalties from injectable drugs support the cash flow of Cara Therapeutics, Inc. (CARA), although the stagnation of new clinical programs reduces overall operational resilience. This metric measures the daily efficiency of the core business excluding depreciation and amortization, allowing investors to assess the maturity of cash inflows and revenue volatility, which is clearly reflected in the trend of operational accruals before depreciation.